文献速递艾滋病与性传播感染

五日服两日停(FOTO)比克替拉韦方案的随机对照试验

Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

主要终点为比克替拉韦谷浓度>162 ng/mL,FOTO组第4、28、52周达标率分别为90%、93.3%、100%,病毒学抑制与每日组相当,提示FOTO方案可行。

要点

  • FOTO组比克替拉韦谷浓度>162 ng/mL比例第4周90%、第28周93.3%、第52周100%。
  • FOTO组病毒学抑制(PVL<50 copies/mL)与每日组相似,未见显著差异。
  • FOTO组5例谷浓度<162 ng/mL者均维持病毒学抑制。

核心结论

  • HIV感染者采用FOTO比克替拉韦方案可维持足够的比克替拉韦暴露和病毒学抑制。

主要发现

  • FOTO组第4、28、52周比克替拉韦Ctrough>162 ng/mL的比例分别为90%、93.3%、100%。
  • 意向性分析中,FOTO组第4、28、52周PVL<50 copies/mL比例分别为100%、93.3%、100%,每日组分别为96.7%、93.3%、96.7%。
  • FOTO组第4周和第28周Ctrough<162 ng/mL的5例参与者均维持PVL<50 copies/mL。
  • 57例(95.0%)进入延伸期,56例(98.2%)完成研究,延伸期第48周所有参与者维持PVL<50 copies/mL。

关键数值与推荐

  • 主要终点为第4、28、52周血浆比克替拉韦Ctrough>体外蛋白校正95%有效浓度(162 ng/mL)。
  • 次要终点包括同时间点PVL<50 copies/mL及体重、肾脏和代谢参数。

临床怎么用

  • 对于已稳定抑制的HIV感染者,FOTO比克替拉韦方案可作为每日服药的一种潜在替代策略。
  • 采用FOTO方案时需关注比克替拉韦谷浓度,但本研究中短暂低于162 ng/mL者仍维持病毒学抑制。

局限性

  • 原文未报告样本量计算、统计学效能及不良事件详细数据。
  • 开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This open-label, randomized clinical trial determined plasma bictegravir trough concentration (Ctrough) and compared virological efficacy with daily bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) versus BIC/FTC/TAF taken five-days-on-two-days-off (FOTO) in people with HIV (PWH). METHODS: Sixty PWH aged ≥20 years with plasma HIV RNA load (PVL) of <50 copies/mL for ≥6 months after having received daily BIC/FTC/TAF were randomized (1:1) to daily versus FOTO BIC/FTC/TAF. The primary endpoint was plasma bictegravir Ctrough above the in vitro protein-adjusted 95% effective concentration (162 ng/mL) at Weeks 4, 28 and 52. The secondary endpoints were PVL < 50 copies/mL and weight and renal and metabolic parameters at the same time points. After Week 52, all participants entered the 48-week extension phase to receive FOTO BIC/FTC/TAF. RESULTS: There were no significant differences in the baseline clinical characteristics, including drug-metabolizing gene polymorphisms, between the two groups. In the FOTO group, 90%, 93.3% and 100% of participants achieved a bictegravir Ctrough of >162 ng/mL at Weeks 4, 28 and 52, respectively. In intention-to-treat analysis, PVL of <50 copies/mL at Weeks 4, 28 and 52 was achieved by 100%, 93.3% and 100%, respectively, in the FOTO group, compared with 96.7%, 93.3% and 96.7% in the daily group. All five participants in the FOTO group with bictegravir Ctrough of <162 ng/mL at Weeks 4 and 28 maintained PVL <50 copies/mL. Of 57 (95.0%) participants who entered the extension phase, 56 (98.2%) completed the study and all maintained PVL <50 copies/mL at extension Week 48. CONCLUSIONS: We showed PWH could successfully maintain sufficient bictegravir exposure and virological suppression with FOTO BIC/FTC/TAF. CLINICAL TRIALS REGISTRATION: NCT06773754.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Sun HY, Lin YT, Chang WC, et al. Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial. J Antimicrob Chemother. 2025. PMID: 40470796. doi:10.1093/jac/dkaf186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。